Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1429
Shown on this page
12
Current sort
Recently updated
Campus scope
Johns Hopkins, Baltimore, MD
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Johns Hopkins, Baltimore, MD. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 409–420 of 1,429 matching trials with a site at Johns Hopkins, Baltimore, MD.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

NCT05141513
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796
Status at this site: Recruiting
View directory record Official record
Conditions
Neoplasms
Interventions
Gene-modified (GM) T cell therapy
Genetic
Lead sponsor
Celgene
Industry
Eligibility
Not listed
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
103
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Active, not recruiting Not applicable Interventional

Optimal Stent Duration After Ureteroscopy

NCT06045962
Site status not listed — check the official record
View directory record Official record
Conditions
Ureteral Stent
Interventions
Ureteral stent
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional

Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

NCT06123481
Status at this site: Recruiting
View directory record Official record
Conditions
Osteonecrosis of the Femoral Head, Avascular Necrosis of the Femoral Head
Interventions
Core Decompression, Core Decompression Procedure with Autologous Bone Marrow Aspirate Concentrate
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

NCT06287775
Status at this site: Recruiting
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
Status at this site: Recruiting
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT07349537
Status at this site: Recruiting
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
Interventions
RMC-5127, daraxonrasib, cetuximab
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

NCT07103746
Status at this site: Recruiting
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Ublituximab, Placebo for Ublituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates

NCT06075745
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Transplant
Interventions
CMV-MVA Triplex, Placebo for CMV-MVA Triplex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • La Jolla, California • Redwood City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 2:42 PM EDT

About this Johns Hopkins institution page

What this page lists
ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.